End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,390 KRW | 0.00% | +14.90% | -41.13% |
25/04 | Noul Announces 2 Clinical Performance Studies At Pan-African Malaria Conference | CI |
2023 | Noul Co., Ltd. Unveils the Result of Malaria Study in Ethiopia and Ghana | CI |
Sales 2022 | 542M 398K 33.17M | Sales 2023 | 2.73B 2.01M 167M | Capitalization | 150B 110M 9.18B |
---|---|---|---|---|---|
Net income 2022 | -13.68B -10.04M -837M | Net income 2023 | -16.32B -11.98M -999M | EV / Sales 2022 | 182 x |
Net Debt 2022 | 140M 103K 8.6M | Net cash position 2023 | 11.81B 8.67M 723M | EV / Sales 2023 | 50.5 x |
P/E ratio 2022 |
-6.92
x | P/E ratio 2023 |
-6.67
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.57% |
1 week | +14.90% | ||
Current month | +3.46% | ||
1 month | -7.18% | ||
3 months | -24.96% | ||
6 months | -47.93% | ||
Current year | -41.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chan-Young Im
CEO | Chief Executive Officer | 45 | 01/15/01 |
Ri-Hyeon Kim
DFI | Director of Finance/CFO | 42 | 01/20/01 |
Dong-Young Lee
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chan-Young Im
CEO | Chief Executive Officer | 45 | 01/15/01 |
Dong-Young Lee
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/15/01 |
Kyung-Hwan Kim
BRD | Director/Board Member | 45 | - |
Date | Price | Change | Volume |
---|---|---|---|
03/24/03 | 2,390 | 0.00% | 276,184 |
02/24/02 | 2,390 | +3.46% | 649,530 |
30/24/30 | 2,310 | +0.87% | 412,412 |
29/24/29 | 2,290 | +10.10% | 1,184,418 |
26/24/26 | 2,080 | -1.65% | 186,645 |
End-of-day quote Korea S.E., May 03, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-41.13% | 65.18M | |
-16.10% | 11.41B | |
+67.65% | 3.81B | |
-14.31% | 2.16B | |
-26.03% | 1.56B | |
+36.95% | 1.19B | |
-2.40% | 760M | |
-19.00% | 506M | |
-38.57% | 444M | |
+13.72% | 339M |
- Stock Market
- Equities
- A376930 Stock